Pfizer Sees Bright Long Term Biosimilar Future In China

Despite shorter term general cost pressures and the time needed for approval reviews, Pfizer sees a strong future for its biosimilar operations in China, as it recorded a solid second quarter performance for its traditional franchises and unveiled a series of new health alliances in this key emerging market.